Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

[News]

Patients with chronic myeloid leukaemia who use the tyrosine kinase inhibitor imatinib may be three to four times more likely to develop non-Hodgkin's lymphoma than the general population, study findings indicate.

More... (http://www.news-medical.net/news/20160317/Secondary-non-Hodgkins-lymphoma-a-concern-for-CML-patients-using-TKIs.aspx)